Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Filings indexed 243 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Regulatory Filings Classification · 86% confidence The document is a short intimation under SEBI LODR Regulation 29 to stock exchanges notifying the date of a Board meeting to consider and approve audited financial results. It does not contain any financial data or report itself, nor is it announcing a change in board composition. It is a regulatory compliance announcement. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-21 English
Price movement
Regulatory Filings
2026-04-15 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-13 English
Outcome of Board Meeting
Regulatory Filings
2026-03-27 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the closure of the trading window for insiders due to upcoming audited financial results for the quarter and financial year ending March 31, 2026. It references SEBI regulations on insider trading and informs about the trading restrictions period. The document does not contain any financial data, results, or detailed report content itself. It is a regulatory announcement related to insider trading compliance and trading restrictions, not the financial report or earnings release. The document length is short (1934 characters), and it serves as a notification to the exchanges rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS).
2026-03-26 English
Price movement
Regulatory Filings
2026-03-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.